niceritrol has been researched along with Hyperlipidemias in 13 studies
Niceritrol: An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The relation of plasma levels of prostaglandins to the occurrence of flushing induced by niceritrol was investigated." | 7.67 | Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing. ( Kameda, K; Kihara, S; Kubo, M; Matsuzawa, Y; Nozaki, S; Tarui, S, 1987) |
| " We administered niceritrol, a nicotinic acid derivative, to patients with chronic renal disease and a high serum Lp(a) level, and studied its effects on lipid metabolism, proteinuria, and renal function." | 5.10 | Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. ( Hata, T; Owada, A; Suda, S, 2003) |
| "The relation of plasma levels of prostaglandins to the occurrence of flushing induced by niceritrol was investigated." | 3.67 | Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing. ( Kameda, K; Kihara, S; Kubo, M; Matsuzawa, Y; Nozaki, S; Tarui, S, 1987) |
| "It is recommended for patients with hyperlipemia alone, or those who suffer from combined erectile dysfunction." | 2.67 | [The clinical effect of slow releasing nicotinate on hyperlipemic impotent patients]. ( Hwang, TI; Yang, CR, 1993) |
| "Pentaerythritol tetranicotinate (Perycit), at an oral dosage of 750 mg daily, was given to 12 patients with idiopathic hyperlipidemia and to 12 patients with hyperlipidemia superimposed with diabetes mellitus (DM)." | 2.66 | The antilipemic effectiveness of pentaerythritol tetranicotinate on hyperlipidemic patients with or without diabetes mellitus--a double-blind, randomized and two-period change-over experiment. ( Chen, JJ; Chen, RL; Chern, JC; Ho, LT; Hsu, SC; Jap, TS; Kwok, CF; Wu, MS, 1985) |
| " Nicotinic acid in the form of niceritrol had another type of dose-response in type II with doses from 3 to 6 g/day." | 1.25 | Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia. ( Carlson, LA; Olsson, AG; Orö, L; Rössner, S, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (53.85) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Owada, A | 1 |
| Suda, S | 1 |
| Hata, T | 1 |
| Fujioka, T | 1 |
| Ueno, T | 1 |
| Matsumoto, T | 1 |
| Watanabe, H | 1 |
| Hwang, TI | 1 |
| Yang, CR | 1 |
| Teramoto, T | 1 |
| Yamada, N | 1 |
| Shimano, H | 1 |
| Oka, Y | 1 |
| Itakura, H | 2 |
| Saito, Y | 1 |
| Morisaki, N | 1 |
| Shirai, K | 1 |
| Ishikawa, T | 1 |
| Tada, N | 1 |
| Ito, H | 1 |
| Yamanouchi, T | 1 |
| Matsushima, T | 1 |
| Kawakami, M | 1 |
| Murase, T | 1 |
| Okubo, M | 1 |
| Totsuka, Y | 1 |
| Kikuchi, M | 1 |
| Britov, AN | 1 |
| Shmushkovich, BI | 1 |
| Karmanskiĭ, IM | 1 |
| Orö, L | 2 |
| Olsson, AG | 2 |
| Rössner, S | 2 |
| Carlson, LA | 1 |
| Lundholm, L | 1 |
| Jacobsson, L | 1 |
| Brattsand, R | 1 |
| Magnusson, O | 1 |
| Hansen, PF | 1 |
| Mimura, K | 1 |
| Yukawa, S | 1 |
| Nozaki, S | 1 |
| Kihara, S | 1 |
| Kubo, M | 1 |
| Kameda, K | 1 |
| Matsuzawa, Y | 1 |
| Tarui, S | 1 |
| Ho, LT | 1 |
| Chern, JC | 1 |
| Hsu, SC | 1 |
| Chen, RL | 1 |
| Kwok, CF | 1 |
| Wu, MS | 1 |
| Chen, JJ | 1 |
| Jap, TS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment[NCT00108485] | Phase 3 | 9 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Unable to recruit sufficient study subjects) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00108485)
Timeframe: Baseline, 1 year
| Intervention | mg/dL (Number) |
|---|---|
| Extended Release Niacin | 42 |
| Placebo | 63 |
1 review available for niceritrol and Hyperlipidemias
| Article | Year |
|---|---|
[Dyslipidemia in renal failure].
Topics: Arteriosclerosis; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Coronar | 2004 |
4 trials available for niceritrol and Hyperlipidemias
| Article | Year |
|---|---|
Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial.
Topics: Chronic Disease; Creatinine; Disease Progression; Female; Humans; Hyperlipidemias; Hypolipidemic Age | 2003 |
[The clinical effect of slow releasing nicotinate on hyperlipemic impotent patients].
Topics: Delayed-Action Preparations; Erectile Dysfunction; Humans; Hyperlipidemias; Male; Niceritrol; Single | 1993 |
The effects of different dose regimens of niceritrol of serum lipid concentrations in man.
Topics: Administration, Oral; Cholesterol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Hu | 1976 |
The antilipemic effectiveness of pentaerythritol tetranicotinate on hyperlipidemic patients with or without diabetes mellitus--a double-blind, randomized and two-period change-over experiment.
Topics: Clinical Trials as Topic; Diabetes Complications; Double-Blind Method; Humans; Hyperlipidemias; Nice | 1985 |
8 other studies available for niceritrol and Hyperlipidemias
| Article | Year |
|---|---|
Dose-dependent effect of niceritrol on plasma lipoprotein-a.
Topics: Aged; Dose-Response Relationship, Drug; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipop | 1996 |
[Treatment of ischemic heart disease with a hypolipoproteinemic drug pericit].
Topics: Adult; Aged; Cholesterol; Coronary Disease; Drug Evaluation; Female; Humans; Hyperlipidemias; Lipopr | 1977 |
Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
Topics: Cholestyramine Resin; Clofibrate; Dose-Response Relationship, Drug; Drug Therapy, Combination; Human | 1975 |
Influence of nicotinic acid, niceritrol and beta-pyridylcarbinol on experimental hyperlipidemia and atherosclerosis in mini-pigs.
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Coronary Vessels; Humans; Hyperlipidemias; Lipoprotei | 1978 |
Differential drug therapy of the hyperlipoproteinaemias. The efficacy of lipid lowering drugs alone and in combination.
Topics: Cholesterol; Clofibrate; Drug Synergism; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypolip | 1975 |
[Treatment of hyperlipidemia].
Topics: Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Dieta | 1992 |
[Hyperlipidemia and drug treatment].
Topics: Arteriosclerosis; Carnitine; Cholestyramine Resin; Glomerulonephritis; Humans; Hyperlipidemias; Kidn | 1991 |
Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aspirin; Cholesterol; Dinoprostone; Flushing; Humans; Hyp | 1987 |